The mode of death in implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillator patients: Results from routine clinical practice

被引:29
|
作者
Thijssen, Joep [1 ]
van Rees, Johannes B. [1 ]
Venlet, Jeroen [1 ]
Borleffs, C. Jan Willem [1 ]
Hoke, Ulas [1 ]
Putter, Hein [2 ]
van der Velde, Enno T. [1 ]
van Erven, Lieselot [1 ]
Schalij, Martin J. [1 ]
机构
[1] Leiden Univ, Dept Cardiol, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Dept Med Stat, Med Ctr, NL-2300 RC Leiden, Netherlands
关键词
Mortality; Implantable cardioverter-defibrillator; Mode of death; Cardiac resynchronization therapy with defibrillator; Sudden cardiac death; NONISCHEMIC DILATED CARDIOMYOPATHY; ANTIARRHYTHMIC-DRUG THERAPY; CHRONIC HEART-FAILURE; BYPASS GRAFT-SURGERY; RANDOMIZED-TRIAL; HIGH-RISK; VENTRICULAR ARRHYTHMIAS; SECONDARY PREVENTION; ESC GUIDELINES; SUDDEN-DEATH;
D O I
10.1016/j.hrthm.2012.04.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Although data on the mode of death of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy with defibrillator (CRT-D) patients have been examined in randomized clinical trials, in routine clinical practice data are scarce. To provide reasonable expectations and prognosis for patients and physicians, this study assessed the mode of death in routine clinical practice. OBJECTIVE To assess the mode of death in ICD/CRT-D recipients in routine clinical practice. METHODS All patients who underwent an ICD or CRT-D implantation at the Leiden University Medical Center, the Netherlands, between 1996 and 2010 were included. Patients were divided into primary prevention ICD, secondary prevention ICD, and CRT-D patients. For patients who died during follow-up, the mode of death was retrieved from hospital and general practitioner records and categorized according to a predetermined classification: heart failure death, other cardiac death, sudden death, noncardiac death, and unknown death. RESULTS A total of 2859 patients were included in the analysis. During a median follow-up of 3.4 years (interquartile range 1.7-5.7 years), 107 (14%) primary prevention ICD, 253 (28%) secondary prevention ICD, and 302 (25%) CRT-D recipients died. The 8-year cumulative incidence of all-cause mortality was 39.9% (95% confidence interval 37.0%-42.9%). Heart failure death and noncardiac death were the most common modes of death for all groups. Sudden death accounted for approximately 7%-8% of all deaths. CONCLUSION For all patients, heart failure and noncardiac death are the most common modes of death. The proportion of patients who died suddenly was low and comparable for primary and secondary ICD and CRT-D patients.
引用
收藏
页码:1605 / 1612
页数:8
相关论文
共 50 条
  • [1] Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator
    Daubert, J. Claude
    Leclercq, Christophe
    Mabo, Philippe
    EUROPACE, 2009, 11 : 87 - 92
  • [2] Implantable cardioverter-defibrillator therapy in clinical practice
    Cesario, DA
    Dec, GW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1507 - 1517
  • [3] Incidence of Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure Treated With Combined Cardiac Resynchronization Plus Implantable Cardioverter-Defibrillator Therapy Versus Implantable Cardioverter-Defibrillator Therapy
    Desai, Harit
    Aronow, Wilbert S.
    Ahn, Chul
    Tsai, Fausan S.
    Lai, Hoang M.
    Gandhi, Kaushang
    Amin, Harshad
    Frishman, William H.
    Kalapatapu, Kumar
    Cohen, Martin
    Sorbera, Carmine
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2010, 15 (01) : 37 - 40
  • [4] Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone
    Masoudi, Frederick A.
    Mi, Xiaojuan
    Curtis, Lesley H.
    Peterson, Pamela N.
    Curtis, Jeptha P.
    Fonarow, Gregg C.
    Hammill, Stephen C.
    Heidenreich, Paul A.
    Al-Khatib, Sana M.
    Piccini, Jonathan P.
    Qualls, Laura G.
    Hernandez, Adrian F.
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (09) : 603 - U148
  • [5] Implantable cardioverter-defibrillator and cardiac resynchronization therapy in patients with left ventricular noncompaction
    Kobza, Richard
    Steffel, Jan
    Erne, Paul
    Schoenenberger, Andreas W.
    Huerlimann, David
    Luescher, Thomas F.
    Jenni, Rolf
    Duru, Firat
    HEART RHYTHM, 2010, 7 (11) : 1545 - 1549
  • [6] Cardiac resynchronization and implantable cardioverter defibrillator therapy:: Preliminary results from the InSync Implantable Cardioverter Defibrillator Italian Registry
    Gasparini, M
    Lunati, M
    Bocchiardo, M
    Mantica, M
    Gronda, E
    Frigerio, M
    Caponi, D
    Carboni, A
    Boriani, G
    Zanotto, G
    Ravazzi, PA
    Curnis, A
    Puglisi, A
    Klersy, C
    Vicini, I
    Cavaglià, S
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2003, 26 (01): : 148 - 151
  • [7] Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy
    Kühlkamp, V
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 790 - 797
  • [9] Primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator in elderly patients: results of a Spanish multicentre study
    Exposito, Victor
    Rodriguez-Manero, Moises
    Gonzalez-Enriquez, Susana
    Arias, Miguel A.
    Miguel Sanchez-Gomez, Juan
    Andres La Huerta, Ana
    Bertomeu-Gonzalez, Vicente
    Arce-Leon, Alvaro
    Teresa Barrio-Lopez, Maria
    Arguedas-Jimenez, Hugo
    Garcia Seara, Javier
    Rodriguez-Entem, Felipe
    EUROPACE, 2016, 18 (08): : 1203 - 1210
  • [10] Statins Reduce Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Failure and Combined Heart Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy
    Desai, Harit
    Aronow, Wilbert S.
    Tsai, Fausan S.
    Ahn, Chu
    Lai, Hoang M.
    Amin, Harshad
    Gandhi, Kaushang
    Frishman, William H.
    Cohen, Martin
    Sorbera, Carmine
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 14 (03) : 176 - 179